Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward - Value in Health
FDA Facts: Biomarkers and Surrogate Endpoints | FDA
Advantages and risks or limitations of surrogate endpoints put forward... | Download Table
Trial endpoints: is it time to get selective on surrogate endpoints?
Surrogate Endpoints In Cancer Trials - Drug Discovery World (DDW)
General and Statistical Hierarchy of Appropriate Biologic Endpoints
Surrogate Endpoints | Evidera
The Ongoing Evolution of Endpoints in Oncology | Semantic Scholar
2 Review: Evaluating and Regulating Biomarker Use | Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease |The National Academies Press
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines | SpringerLink
Surrogate Endpoints And FDA's Accelerated Approval Process | Health Affairs
The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions - ScienceDirect
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure | Circulation
Surrogate Endpoints in Infectious Diseases Trials: FDA Perspective Surrogate Endpoints in Infectious Diseases Trials: FDA Perspective John H. Powers, MD. - ppt download
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework | Nature Reviews Drug Discovery
Clinical Trial Endpoints for Oncology Studies
Biomarkers and surrogate endpoints in glaucoma clinical trials | British Journal of Ophthalmology
Surrogate endpoints in EBM: What are the benefits and dangers? - Students 4 Best Evidence
Surrogate Endpoints and Biomarkers | Basicmedical Key
Surrogate Endpoint | Definitive Healthcare
Surrogate Endpoints In Cancer Trials - Drug Discovery World (DDW)
ISPOR - The Use of Surrogate Endpoints in Regulatory and HTA Submissions
